BTG brushes off antivenin sales glitch
This article was originally published in Scrip
Executive Summary
BTG says a drop in first-half sales of the snake bite antidote that it acquired with Protherics in December 2008 was a one-off "timing issue", related to technical problems at a third-party supplier. It said that the end-user market had suffered no shortage because its partner Nycomed had sufficient inventory. The problems have now been resolved with a recovery plan in place meaning that the shortfalls should be made up in the second half of the UK speciality pharmaceutical company's financial year.